The Technology
Otomagnetics is developing and commercializing a magnetic injection delivery system that will be able to safely, effectively, and non-invasively deliver therapy to targets in the body that are currently not effectively reached by the standards-of-care, or that may otherwise require surgery to reach.
The product will be a drug delivery platform
The product combines our proprietary device (a magnetic injector) with bio-degradable magnetic particles (composed solely out of materials approved by the FDA for injection into the body). These particles may be able to carry essentially any therapy (drugs, proteins, or genes).
There are multiple large markets with unmet medical needs that this technology potentially addresses. The cochlea is not adequately reached by current administration methods (e.g. by oral or trans-tympanic administration methods). Magnetic injection can deliver therapy to both cochlear and middle ear compartments. Animal studies have shown safety and efficacy for treating hearing loss, tinnitus, middle ear infections, and for protecting hearing from chemotherapy regimens. Delivery into the eye to the retina (e.g. for macular degeneration), currently requires needle insertions into the eye. Magnetic injection can deliver therapy to the retina, without needles.
The same device and particles have also shown a therapeutic effect in animals efficacy for treating noise induced hearing loss, for reversing tinnitus, for protecting hearing from cisplatin chemotherapies, and for clearing middle ear infections. Potential eye indications include macular degeneration, glaucoma, and treatment of corneal conditions. Our company thus has a platform technology, and has already garnered interest from multiple pharmaceutical companies who see a competitive advantage (and thus increased market share) in being able to non-invasively deliver their proprietary compounds to ear and eye targets.
